CClinicalTrials.gg
CompletedNCT04638907NMBUroUpdated Nov 20, 2020

Fine Tuning of Neuro-muscular Blockade in Robot-assisted Prostatectomy

An observational study in Maintenance of Deep NM Block Without Overdosing, sponsored by Peter Biro. Completed at 1 site in Switzerland. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Peter Biro · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 90 Years
Sex
Male
01

Study summary

Assessing the routinely used protokoll for deep NM Block during robot-assisted prostatectomy in general anesthesia. The protocoll contains the repeated dosing of rocuronium according to the results of relaxometry performed with a TOFcuff relaxometer (RGB Medical, Madrid) during pneumoperitoneum. This is done by keeping the block level between 1 to 6 PTC (post tetanic counts). The scope of the study was to find out, to which percentage this protocoll permits the maintenance of block level inside of the desired range.

Read the detailed description

Robot-assisted urological interventions require sufficiently deep neuromuscular relaxation (NMR) during the phase of pneumoperitoneum. This is achieved by repeated administration of the non-depolarizing neuromuscular relaxant rocuronium, which is used in clinical routine. The level of relaxation is usually measured with the TOF-Watch relaxometer. This device has limitations in its usability and accuracy in this setting because it is unreliable when the monitored arm of the patient is not accessible for the anaesthetist for visual or tactile assessment of finger movements. The novel TOF-Cuff relaxometry equipment is by design intended to provide constant and reliable quantitative and in vivo calibrated relaxometric values independently of the arm position. The combination of frequently adjusted neuromuscular relaxation in a standardised mode in combination with a reliable relaxometry by TOFcuff promises an improved surveillance of neuromuscular relaxation and a higher safety standard. This investigation aims to test and to define the combined use of the best available drug with the best available relaxometer for general anesthesia in robot-assisted urological surgery.

02

Conditions studied

  • Maintenance of Deep NM Block Without Overdosing

Keywords

  • neuromuscular block, robot-assisted prostatectomy
03

In context

Lead sponsor

This is the only study on the registry with Peter Biro as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

Unselected pateints, who fulfil the inclusion criteria as they become available for anesthesia and surgery.

Inclusion criteria

  • consenting male adults undergoing elective robot-assisted urological surgery.

Exclusion criteria

Exclusion Criteria:

  • Emergency cases, Patients who don't understand the requirements of the study and don't agree to sign the informed consent. Contraindication to neuromuscular relaxation with rocuronium.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Observational study group

    Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.

    Procedure: Assessment of NM block

Interventions

  • ProcedureAssessment of NM block

    Observation of resulting course of NM block under teratment and monitoring as described.

06

What researchers measure

Primary outcomes

  1. Successful deep NM block

    Time percentage of optimal NM block during pneumoperitoneum

    Time frame: Entire duration of pneumoperitoneum varying between 2 and 5 hours.

Secondary outcomes

  1. Surgeon's satisfaction

    Overall subjective satisfaction with the patient's relaxation by the surgeon on a verbal rating scale (1 = extremely bad; 10 = excellent)(Staehr-Rye 2014)

    Time frame: Duration of pneumoperitoneum

07

Study locations

1 site
  • University Hospital Zurich, Institue of Anesthesiology
    Zurich, ZH 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: No — No plan to share the obtained data.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04638907
Lead sponsor
Peter Biro
Responsible party
Peter Biro (Prof. Dr. med., University of Zurich) — Sponsor-investigator
First posted
Nov 20, 2020
Start date
Jan 15, 2017
Primary completion
Jul 15, 2019
Completion
Dec 15, 2019
Last update
Nov 20, 2020

Study contacts

Donat R Spahn, Prof. Dr.
study chair · Institute of Anesthesiology, University Hospital Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion